Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Equity Average (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 10 years of Equity Average data on record, last reported at $90.0 million in Q4 2025.

  • For Q4 2025, Equity Average fell 72.49% year-over-year to $90.0 million; the TTM value through Dec 2025 reached $90.0 million, down 72.49%, while the annual FY2025 figure was $176.4 million, 58.12% down from the prior year.
  • Equity Average reached $90.0 million in Q4 2025 per SNDX's latest filing, down from $136.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $523.0 million in Q1 2024 and bottomed at $90.0 million in Q4 2025.
  • Average Equity Average over 5 years is $328.4 million, with a median of $359.1 million recorded in 2022.
  • Peak YoY movement for Equity Average: soared 464.44% in 2021, then tumbled 72.49% in 2025.
  • A 5-year view of Equity Average shows it stood at $303.7 million in 2021, then soared by 32.63% to $402.8 million in 2022, then grew by 13.39% to $456.7 million in 2023, then decreased by 28.34% to $327.3 million in 2024, then crashed by 72.49% to $90.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $90.0 million in Q4 2025, $136.4 million in Q3 2025, and $186.2 million in Q2 2025.